Back to Annual Meeting

Back to Annual Meeting

Abstract #162347

Firouz Daneshgari, MD, Glickman Urological Insitute, Cleveland Clinic Foundation, 9500 Euclid Avenue/A100, Cleveland, OH 44195, Peter Imrey, PhD, Dept. of Quantitative Health Sciences, Cleveland Clinic and Case Western Reserve University, 9500 Euclid Avenue/Wb4, Cleveland, OH 44195, 216-444-0923, imreyp@ccf.org, Betsy Risendal, PhD, S/M Cancer Center (UCDHSC) - Cancer Prevention & Control Division, University of Colorado Health Science Center, Campus Box F538, Fitzsimons Bldg. 500, Room E4314, Denver, CO 80262, Andrea Dwyer, University of Colorado School of Medicine, 13001 E. 17th Place, MSf538, P.O. Box 6508, Aurora, CO 80045, Matthew Barber, MD, MHS, Dept.of Obstetrics and Gynecology, Cleveland Clinic Foundation, 9500 Euclid Avenue/A81, Cleveland, OH 44195, and Tim Byers, MD, MPH, Dept. of Preventive Medicine and Biometrics, University of Colorado Health Science Center, Campus Box B119, 4200 E. 9th Avenue, Denver, CO 80262.

Prevalent urinary incontinence (UI), operationally defined as weekly leakage of a few drops of urine or greater leakage at least monthly, was studied in relation to ethnicity, breast cancer, and adjuvant breast cancer therapies. Participants were consenting Colorado residents in the Southwest Study of Hormones, Insulin, Nutrition, and Exercise (SHINE), a multi-state population-based breast cancer case-control study. The 741 participants in our SHINE/Women's Pelvic Health Study (SHINE/WPH) included 379 breast cancer cases, 362 controls, 250 Hispanic, and 491 non-Hispanic White women. Hispanic women reported more stress UI (OR=1.7, p=.005) and mixed UI (OR=1.8, p=.005) than non-Hispanic White women. However, these elevated risks among Hispanics were largely accounted for by their higher prevalences of known UI risk factors, including parity, adiposity, and diabetes. Although several breast cancer risk factors are protective against UI, UI prevalence among SHINE/WPH breast cancer cases was similar to that of population controls, and modestly though non-significantly higher after adjustment for risk factors (adjusted OR = 1.29, 95% CI 0.90 – 1.85). UI prevalences among breast cancer patients receiving adjuvant chemotherapy or anti-hormonal therapy were compared respectively to breast cancer cases not receiving the corresponding therapy, and to population controls. Overall, prevalence of stress UI was elevated among breast cancer cases who had previously been treated by chemotherapy (OR=1.7, P=.02), and among breast cancer cases who had received anti-hormonal therapies. (OR=1.6, P=.02). In models incorporating both therapies, chemotherapy retained significance (OR=1.7, p=.05). More research is needed on variations in UI according to both ethnicity and prior cancer therapies.

Learning Objectives:

• Assess how Hispanic women differ from non-Hispanic white women, and women who contract breast cancer differ from women who do not, in their distributions of risk factors for urinary incontinence.
• Distinguish between the crude and risk-factor adjusted relationships of Hispanic ethnicity to urinary incontinence prevalence in Colorado participants in the Southwest Study of Hormones, Insulin, Nutrition and Health, Women’s Pelvic Health (SHINE/WPH) Study.
• Describe suggestive results in Colorado SHINE/WPH participants linking urinary incontinence to breast cancer therapies

Keywords: Women's Health, Hispanic

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.